Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100P1F0
Period2022-01-01 → 2022-06-30
Filed2022-08-15
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥6.5bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥2.6bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥682m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥522m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥941m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥509m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥745m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥309m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥35.3bnat 2022-06-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥13.5bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.1bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥17.9bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥2.9bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.32021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.782021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.732021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥10.592021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.9%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-06-30¥390m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-06-30¥1.1bn
—segment totalrevenue2021-01-01 → 2021-06-30¥6.5bn
—segment totalrevenue external2021-01-01 → 2021-06-30¥6.5bn
—segment totalsegment profit2021-01-01 → 2021-06-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Basic earnings loss per share IFRSPrior1YTDDuration20.30
Basic earnings loss per share IFRSCurrentYTDDuration14.25
Diluted earnings loss per share IFRSPrior1YTDDuration19.73
Diluted earnings loss per share IFRSCurrentYTDDuration14.18
Revenue IFRSPrior1QuarterDuration2592819000JPY
Revenue IFRSCurrentQuarterDuration4221327000JPY
Cost of sales IFRSPrior1QuarterDuration329974000JPY
Cost of sales IFRSCurrentQuarterDuration585213000JPY
Gross profit IFRSPrior1QuarterDuration2262844000JPY
Gross profit IFRSCurrentQuarterDuration3636114000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration1483509000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration2307425000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration461243000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration620669000JPY
Other income IFRSPrior1QuarterDuration415511000JPY
Other income IFRSCurrentQuarterDuration14751000JPY
Other expenses IFRSPrior1QuarterDuration51551000JPY
Other expenses IFRSCurrentQuarterDuration197029000JPY
Operating profit loss IFRSPrior1QuarterDuration682051000JPY
Operating profit loss IFRSCurrentQuarterDuration525741000JPY
Finance income IFRSPrior1QuarterDuration4585000JPY
Finance income IFRSCurrentQuarterDuration121102000JPY
Finance costs IFRSPrior1QuarterDuration165024000JPY
Finance costs IFRSCurrentQuarterDuration203881000JPY
Profit loss before tax IFRSPrior1QuarterDuration521612000JPY
Profit loss before tax IFRSCurrentQuarterDuration442962000JPY
Income tax expense IFRSPrior1QuarterDuration212549000JPY
Income tax expense IFRSCurrentQuarterDuration317332000JPY
Profit loss IFRSPrior1QuarterDuration309063000JPY
Profit loss IFRSCurrentQuarterDuration125629000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration508780000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration325432000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration-199717000JPY
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration-199802000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration10.78
Basic earnings loss per share IFRSCurrentQuarterDuration6.86
Diluted earnings loss per share IFRSPrior1QuarterDuration10.59
Diluted earnings loss per share IFRSCurrentQuarterDuration6.83
Profit loss IFRSPrior1YTDDuration744778000JPY
Profit loss IFRSCurrentYTDDuration197918000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration902465000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration2136618000JPY
Other comprehensive income IFRSPrior1YTDDuration902465000JPY
Other comprehensive income IFRSCurrentYTDDuration2136618000JPY
Comprehensive income IFRSPrior1YTDDuration1647243000JPY
Comprehensive income IFRSCurrentYTDDuration2334536000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration1713735000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration3018532000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration-66491000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration-683995000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass